Bosl GJ - Search Results

1

Salvage chemotherapy for patients with advanced pure seminoma.

Vuky J, Tickoo SK, Sheinfeld J, Bacik J, Amsterdam A, Mazumdar M, Reuter V, Bajorin DF, Bosl GJ, Motzer RJ. Vuky J, et al. Among authors: bosl gj. J Clin Oncol. 2002 Jan 1;20(1):297-301. doi: 10.1200/JCO.2002.20.1.297. J Clin Oncol. 2002. PMID: 11773182

2

Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors.

Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, Chaganti RS. Rodriguez E, et al. Among authors: bosl gj. Cancer Res. 1992 Apr 15;52(8):2285-91. Cancer Res. 1992. PMID: 1313741

3

High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions.

Motzer RJ, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. J Natl Cancer Inst. 1992 Nov 18;84(22):1703-9. doi: 10.1093/jnci/84.22.1703. J Natl Cancer Inst. 1992. PMID: 1331482 Review.

4

Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

Wood DP Jr, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ. Wood DP Jr, et al. Among authors: bosl gj. J Urol. 1992 Dec;148(6):1812-5; discussion 1815-6. doi: 10.1016/s0022-5347(17)37036-2. J Urol. 1992. PMID: 1331547

5

Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors.

Murty VV, Houldsworth J, Baldwin S, Reuter V, Hunziker W, Besmer P, Bosl G, Chaganti RS. Murty VV, et al. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):11006-10. doi: 10.1073/pnas.89.22.11006. Proc Natl Acad Sci U S A. 1992. PMID: 1332066 Free PMC article.

6

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. Semin Oncol. 1992 Dec;19(6 Suppl 12):8-11. Semin Oncol. 1992. PMID: 1336624

7

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

Murphy BA, Motzer RJ, Bosl GJ. Murphy BA, et al. Among authors: bosl gj. Invest New Drugs. 1992 Nov;10(4):327-30. doi: 10.1007/BF00944190. Invest New Drugs. 1992. PMID: 1336770 Clinical Trial.

8

Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Bajorin DF, et al. Among authors: bosl gj. Semin Oncol. 1992 Apr;19(2):148-58. Semin Oncol. 1992. PMID: 1372757 Review.

9

"Poor-risk" germ cell tumors: current progress and future directions.

Motzer RJ, Bajorin DF, Bosl GJ. Motzer RJ, et al. Among authors: bosl gj. Semin Oncol. 1992 Apr;19(2):206-14. Semin Oncol. 1992. PMID: 1372761 Review. No abstract available.

10

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers.

Wood DP Jr, Herr HW, Motzer RJ, Reuter V, Sogani PC, Morse MJ, Bosl GJ. Wood DP Jr, et al. Among authors: bosl gj. Cancer. 1992 Nov 1;70(9):2354-7. doi: 10.1002/1097-0142(19921101)70:9<2354::aid-cncr2820700924>3.0.co;2-u. Cancer. 1992. PMID: 1382832

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

329 results

Search Page

Filters